Hormone-dependent diseases of the female reproductive system in the era of COVID-19: quo vadis?

Хамошина, М.Б.; Zhuravleva, I.S.; Artemenko, Yu.S.; Dmitrieva, E. M.

doi:10.33029/2303-9698-2021-9-3suppi-35-42

Cited by 1 publication

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Increasing the life expectancy of Russians entails a whole range of practically significant problems of organizing medical care for middle-aged women. Disorders related to aging require special attention, among which diseases associated with a deficiency / imbalance of sex hormones occupy a leading position [1][2][3][4].…”

Section: Introductionmentioning

confidence: 99%

“…On the other hand, estrogens have been proven to protect the vascular endothelium, since their expression increases the synthesis of endothelial NO synthase, an enzyme involved in the formation of a powerful vasodilating factor nitric oxide (NO). In addition, estradiol increases the number of CD 4+ T cells, providing an adequate immune response when infected with SARS-CoV-2 [4,8].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Clinical and genetic aspects of menopausal hormone therapy - a modern paradigm. What changed COVID-19 pandemic?

Zhuravleva

Хамошина

Оразов

et al. 2022

Vestn. Ross. univ. družby nar., Ser. Med.

Self Cite

View full text Add to dashboard Cite

In the modern paradigm of public health protection, much attention is paid to the health of women in peri- and postmenopause, and a personalized approach prevails. It is generally recognized that the pathogenetic therapy of menopausal disorders is hormone therapy. But the COVID-19 pandemic has made its own adjustments to the routine strategy of choosing menopausal hormone therapy (MHT). The purpose of this review was to analyze studies on the dependence of the effectiveness of MHT on clinical and genetic aspects in the context of the ongoing COVID-19 pandemic. The review highlights the main risks of MHT for thromboembolic diseases and coagulation complications characteristic of COVID-19, discusses genetic predispositions that aggravate the course of the post-COVID period, as well as the effectiveness of estrogens in protecting the vascular endothelium and increasing the number of CD4+ T cells, providing an adequate immune response when infected with SARS-CoV-2. Numerous studies show that the complications characteristic of the severe course of COVID-19 are multifactorial in nature and cannot be unambiguously explained only by genetic predisposition. However, with the development of personalized medicine, special attention should be paid to the study of genetic aspects that can equally contribute to the occurrence of menopausal disorders in healthy women and aggravate the course of the post-pregnancy period. The data presented allow us to conclude that in the context of the ongoing COVID-19 pandemic at the population level, MHT can bring significant benefits to women during menopause due to the beneficial effect of estrogens on vascular walls. Additional study of the relationship between the course of the postcovid period in MHT users and polymorphisms of candidate genes that determine the risks of thrombotic complications and metabolic consequences is required.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%